The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | How would the approval of luspatercept benefit the treatment landscape in myelofibrosis
In this video, Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, briefly discusses how the potential approval of luspatercept could benefit the treatment landscape of myelofibrosis (MF) in the future. Luspatercept showed encouraging safety and efficacy for treating anemia in ruxolitinib-treated patients in the Phase II ACE-536-MF-001 trial (NCT03194542), and this is being further explored in the Phase III INDEPENDENCE study (NCT04717414). Dr Gerds also highlights the potential for combining luspatercept with JAK inhibitors to improve anemia responses. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology; Research Funding: Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals.
